Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 11, 2021 13:11 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock

LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
February 03, 2021 22:03 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Pricing of Public Offering of Common Stock

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
February 03, 2021 16:10 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Proposed Public Offering of Common Stock

LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the...
January 20, 2021 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference

LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone...
January 14, 2021 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from...
January 05, 2021 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

LEXINGTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc., (Nasdaq: KLDO) today announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P....
January 04, 2021 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19

LEXINGTON, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031...
November 24, 2020 15:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the...
November 02, 2020 07:35 ET | Source: Kaleido Biosciences

Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 2021 - LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc....
October 07, 2020 07:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences

Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020 Data from studies of KB39 and KB174 to be presented at The Liver Meeting®...